英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Overview – Cogent Biosciences, Inc.
    The Investor Relations website contains information about Cogent Biosciences, Inc 's business for stockholders, potential investors, and financial analysts
  • Cogent Biosciences Announces Poster Presentations at the American . . .
    WALTHAM, Mass and BOULDER, Colo , April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that preclinical data from the Company’s KRAS and ErbB2 pipeline programs will be presented during poster sessions at the American Association for Cancer Research
  • Press Releases – Cogent Biosciences, Inc.
    The Investor Relations website contains information about Cogent Biosciences, Inc 's business for stockholders, potential investors, and financial analysts
  • Cogent Biosciences Announces FDA Acceptance of New Drug Application . . .
    The Investor Relations website contains information about Cogent Biosciences, Inc 's business for stockholders, potential investors, and financial analysts
  • Cogent Biosciences Announces Submission of New Drug Application for . . .
    The Investor Relations website contains information about Cogent Biosciences, Inc 's business for stockholders, potential investors, and financial analysts
  • Cogent Biosciences Reports Recent Business Highlights and Third Quarter . . .
    Preclinical data from this program as well as the Company’s H1047R mutant-selective PI3Kα clinical candidate were presented at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
  • Cogent Biosciences Announces Breakthrough Therapy Designation for . . .
    WALTHAM, Mass and BOULDER, Colo , Jan 26, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U S Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in combination with sunitinib for patients with
  • Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK . . .
    WALTHAM, Mass and BOULDER, Colo , April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the results from the Phase 3 PEAK trial have been selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held
  • Cogent Biosciences Reports Recent Business Highlights and Fourth . . .
    The Investor Relations website contains information about Cogent Biosciences, Inc 's business for stockholders, potential investors, and financial analysts
  • investors. cogentbio. com
    The information contained and incorporated by reference in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering speaks only as of the date of this document, unless the information specifically indicates that another date applies Neither the delivery of this prospectus supplement, the





中文字典-英文字典  2005-2009